EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ikena Oncology's enterprise value is $-49.53 Mil.
Ikena Oncology's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $0.66 Mil. Therefore, Ikena Oncology's EV-to-Revenue for today is -75.16.
The historical rank and industry rank for Ikena Oncology's EV-to-Revenue or its related term are showing as below:
IKNA'
s EV-to-Revenue Range Over the Past 10 Years
Min: -75.16 Med: -1.8 Max: 102.73
Current: -75.16
During the past 5 years, the highest EV-to-Revenue of Ikena Oncology was 102.73. The lowest was -75.16. And the median was -1.80.
IKNA's EV-to-Revenue is ranked better than 99.04% of 1042
companies
in the Biotechnology industry
Industry Median: 7.54
vs IKNA: -75.16
As of today (2024-12-14), Ikena Oncology's stock price is $1.65.
Ikena Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.01. Therefore, Ikena Oncology's PS Ratio for today is 117.86.
Ikena Oncology EV-to-Revenue Historical Data
The historical data trend for Ikena Oncology's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ikena Oncology's EV-to-Revenue
For the Biotechnology subindustry, Ikena Oncology's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ikena Oncology's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ikena Oncology's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ikena Oncology's EV-to-Revenue falls into.
Ikena Oncology's current Enterprise Value is $-49.53 Mil.
Ikena Oncology's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ikena Oncology's share price for today is $1.65.
Ikena Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ikena Oncology EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Ikena Oncology's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IKNA has been successfully added to your 